Circular Materials Selected as a Strategic Project by the European Commission Under CRMA
Circular Materials, an Italian company specialized in the recovery and valorization of metals from industrial wastewater, has been selected as a Strategic Project under the Critical Raw Materials Act, along with 3 other projects in Italy and 46 in Europe.
The CRMA aims to secure European access to strategic raw materials, by increasing recycling efforts and reducing dependency on imports. Here Circular Materials plays a key role: the company’s patented innovation, SWaP (Supercritical Water Precipitation), leverages the properties of supercritical water to recover valuable metals with a 99% efficiency rate, preventing the loss of resources and eliminating the production of toxic sludges.
"This is a milestone that validates our commitment to providing a sustainable alternative to traditional mining and a key driver for our scale-up at European level. We will keep working closely with key stakeholders to improve Europe's role in the responsible management of critical resources," stated Marco Bersani, founder and CEO."We have the privilege to thrive in Italy and Europe, where institutions are demonstrating a strong focus and commitment to circularity and sustainability."
Being recognized as a Strategic Project enables Circular Materials to accelerate its industrial development plan, benefiting from streamlined permitting procedures and enhanced access to public funding to establish recovery centers more rapidly across Europe.
The company was founded in 2019 and backed by 360 Capital in 2020, launched its first authorized plant in Padua, where a team of 24 people recovers Nickel, Copper, Tin, Chromium, and precious metals with a processing capacity of about 1,000 tons of wastewater per year. A new plant will be installed in Italy by 2026, with an industrial wastewater treatment capacity of up to 20,000 tons per year and valorization of over 4ktpa in strategic metals, through a network of hubs in key industrial districts across EU by 2030.
Aligned with the Clean Industrial Deal strategy, Circular Materials is positioned as a key partner for strategic industries—including batteries, semiconductors, defense, and aerospace—to become more sustainable and resilient towards the global raw materials challenges.
About Circular Materials
Circular Materials is a groundbreaking company with proprietary technology for the recovery of strategic metals from industrial wastewater through a sustainable and highly efficient process. The company has developed and patented the Supercritical Water Precipitation (SWaP) technology, which simultaneously treats wastewater and recovers metal, eliminating toxic sludge production and significantly reducing environmental impact, both in terms of waste and emissions.
By harnessing the unique properties of supercritical water, Circular Materials offers a competitive, safe, modular, and versatile solution capable of transforming entire industries into sustainability leaders, reducing their environmental impact with a virtuous carbon footprint. For more info: www.circularmaterials.it
View source version on businesswire.com: https://www.businesswire.com/news/home/20250326855252/en/
Contacts
Media contact:
Tiziana Sarto
tiziana.sarto@circularmaterials.it
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom